

## **PSMA PET/CT** REQUISITION

## Molecular Imaging and Therapy - Vancouver PET Reception: (604) 707-5951 PET Fax: (604) 877-6245 Current Date: Referring Physician: For Department use only Phone: \_\_\_\_\_ Fax: \_\_\_\_\_Time: \_\_\_\_ Scan Date: Indication #:\_\_\_\_\_ 1 □ 2 □ Clinical Trial Information (if applicable) Details: Clinical Trial Name: V-T: ☐ Other: \_\_\_\_\_ Routine: Contact Person: Date: \_\_\_\_\_ PET Dr. Initial: \_\_\_\_\_ Phone Number: \_\_\_\_\_ Patient Information Important:Mandatory:Height:\_\_\_\_\_Weight:\_\_\_\_\_(kg / lb)PSA within last 3 months? Value:\_\_\_\_\_\_ Date:\_\_\_\_\_\_ Preferred Name: Middle Date of Birth: D\_\_\_\_\_ M\_\_\_ Y\_\_\_\_ PHN: \_\_\_\_\_ Home Address: ) \_\_\_\_\_ Work: ( ) \_\_\_\_ Mobile: ( ) \_\_\_\_ Home Phone: ( Temporary Address: \_\_\_\_\_ Temporary Phone: ( ) \_\_\_\_\_ Family Physician: ( ) Phone: ( Patient Mobility: Ambulatory ☐ Wheelchair ☐ Stretcher ☐

## **Diagnosis/Pertinent History**

## Indication for PSMA PET/CT Imaging (select one or more criteria below 1 - 6):

- ☐ 1) Localized prostate cancer considered for definitive therapy when conventional imaging is equivocal for metastatic disease.
- □ 2) NCCN high to very high risk localized prostate cancer with negative conventional imaging prior to consideration of curative intent therapy.
- □ 3) Clinically oligometastatic or oligoprogressive disease on prior imaging, being considered for metastases-directed therapy.
  - 4) Localization of biochemical cancer Recurrent (BCR) or Persistent (BCP) prostate cancer following curative-intent therapy in the following settings\*:
    - a. 

      Pathologically node positive post RP with a PSA > 0.1 ng/mL at least 6 weeks after RP.
    - b. BCP with persistently elevated PSA > 0.1 ng/mL on first post RP PSA between 6 weeks and 3 months after Radical Prostatectomy when Gleason Grade Group (ISUP) 4-5.
    - c. BCR with a PSA > 0.2 ng/mL more than 6 weeks post Radical Prostatectomy when either PSA doubling time < 12 months OR Gleason Grade Group (ISUP) 4-5.
    - d. ☐ BCR with a PSA > 0.4 ng/mL more than 6 weeks post Radical Prostatectomy.
    - e. ☐ BCR post curative intent radiotherapy +/- adjuvant hormone therapy: i.e. a rise in PSA of ≥ 2 ng/mL above nadir.
    - ☐ BCR (Increase in PSA to ≥ 0.4 ng/mL) after prostatectomy and salvage radiotherapy +/- hormone therapy, where there is intent for further salvage therapy (e.g., SABR/metastases directed therapy).

before the PET so above the nadir a	an. Progression is defined by a	nemical or imaging progression. Treatment does not need to be discontinued any of the following: A minimum PSA of 2.0 ng/mL and 2 consecutive rises one (<1.7 nmol/L), soft tissue disease progression on chest, abdomen, pelvis 2 new lesions on bone scan.
☐ 6) To determine elig	gibility for PSMA-targeted ra	adioligand therapy.
	not included on this list but done includes expert imaging i	eemed appropriate after consensus at an appropriate BC Cancer Tumour review. Describe below:
requirement prior to re ii) If the initial PSMA PET	questing PSMA PET. is negative, and no treatment	propriate in each setting of criteria 4, if the PSA is very high, but is not a is pursued, a second PSMA PET should not be requested for at least 6 months e BC Cancer Tumour Conference
Does patient require an in	terpreter? Y□N□	Language:
Does patient have any dru	•	
CT scan within 3 months?	•	Date:
MRI scan within 3 months	? Y 🗆 N 🗆	Date:
Nuclear Med scan within 3	months? Y \( \D\)	Date:
Previous PET or PET/CT	scan? Y□N□	Location/date:
Doctor's Signature:		MSP No:
Additional Copies of Repto:		MIGI NO
BC Cancer - Vancouver		April 2025

BC Cancer - Vancouver 600 West 10th Avenue Vancouver, BC www.bccancer.bc.ca